On a CureTalks conversation earlier today with Dr. Carl June of the University of Pennsylvania (UPenn), we learned that his team had very recently treated two men with metastatic, castration-resistant prostate cancer (mCRPC) using chimeric antibody receptor T-cell therapy (CAR-T). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: antibody, CAR-T, chimeric, receptor, T-cell | 9 Comments »
On November 15, our friends at CureTalks will hold a telecon on which there will be a discussion about the current and potential future uses of CAR-T in the treatment of cancer with Prof. Carl June of the University of Pennsylvania. … READ MORE …
Filed under: Drugs in development | Tagged: antigen, CAR-T, chimeric, receptor, T-cell, therapy | Leave a comment »
An article in today’s issue of the New England Journal of Medicine reports data from a Phase II trial of CART therapy in the treatment of patients with acute lymphoblastic leukemia or ALL (an aggressive and difficult to treat form of cancer). This is arguably one of the most exciting papers on the treatment of cancer in the past 50+ years. … READ MORE …
Filed under: Uncategorized | Tagged: antigen, CART, chimeric, CTL019, leukemia, T-cell | Leave a comment »
According to an article in Forbes magazine, information about a Phase I clinical trial of “anti-PSMA designer T cells” in prostate cancer was presented today at the American Association for Cancer Research (AACR) meeting in Denver. … READ MORE …
Filed under: Drugs in development | Tagged: anti-PSMA, immunotherapy, T-cell | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 